Literature DB >> 8518595

Hypercalcaemia with topical calcipotriol.

J F Bourke, J Berth-Jones, P E Hutchinson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8518595      PMCID： PMC1677698          DOI： 10.1136/bmj.306.6888.1344-b

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris.

Authors:  W J Cunliffe; J Berth-Jones; A Claudy; G Fairiss; D Goldin; D Gratton; C A Henderson; C A Holden; W S Maddin; J P Ortonne
Journal:  J Am Acad Dermatol       Date:  1992-05       Impact factor: 11.527

2.  Hypercalcaemia associated with calcipotriol (Dovonex) treatment.

Authors:  K A Hardman; D A Heath; H M Nelson
Journal:  BMJ       Date:  1993-04-03

3.  Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled study.

Authors:  L Dubertret; D Wallach; P Souteyrand; M Perussel; B Kalis; J Meynadier; J Chevrant-Breton; C Beylot; J A Bazex; H J Jurgensen
Journal:  J Am Acad Dermatol       Date:  1992-12       Impact factor: 11.527

4.  A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis.

Authors:  J Berth-Jones; A C Chu; W A Dodd; M Ganpule; W A Griffiths; R P Haydey; M R Klaber; S J Murray; S Rogers; H J Jurgensen
Journal:  Br J Dermatol       Date:  1992-09       Impact factor: 9.302
  4 in total
  2 in total

1.  Safety and efficacy of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase II, open-label trial.

Authors:  M Seyger; W Abramovits; M Liljedahl; M N Hoejen; J Teng
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-02-19       Impact factor: 6.166

2.  Safety and efficacy of topical, fixed-dose combination calcipotriene (0.005%) and betamethasone (0.064% as dipropionate) gel in adolescent patients with scalp and body psoriasis: a phase II trial.

Authors:  L F Eichenfield; D Marcoux; M Kurvits; M Liljedahl
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-01-02       Impact factor: 6.166
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.